Edge Rewrite
everything Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a2325c5b1c73bdc9

Jump to content

Forvisirvat

Edit links
From Wikipedia, the free encyclopedia

Forvisirvat
Clinical data
Other namesSP624
Routes of
administration		Oral[1][2]
Drug classSirtuin-6 (SIRT6) activator[1]
Identifiers
  • (2S,5'R)-7-chloro-3',4-dimethoxy-5'-methyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)spiro[1-benzofuran-2,4'-cyclohex-2-ene]-1',3-dione
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC19H17ClN2O6
Molar mass404.80 g·mol−1
3D model (JSmol)
  • C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(C=C(C(=C3O2)Cl)C4=NN=C(O4)C)OC)OC
  • InChI=1S/C19H17ClN2O6/c1-8-5-10(23)6-13(26-4)19(8)17(24)14-12(25-3)7-11(15(20)16(14)28-19)18-22-21-9(2)27-18/h6-8H,5H2,1-4H3/t8-,19+/m1/s1
  • Key:MIHSWFYCAJWPIS-YLVJLNSGSA-N

Forvisirvat (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name SP-624) is a selective sirtuin-6 (SIRT6) activator which is under development for the treatment of major depressive disorder and schizophrenia.[1][3][4][5][6][2][7] It is taken by mouth.[1][2] The drug produces antidepressant-like effects in multiple animal models of depression.[2] As of January 2025, forvisirvat is in phase 2/3 clinical trials for major depressive disorder and is in phase 1/2 clinical trials for schizophrenia.[1][3][5] It is under development by Sirtsei Pharmaceuticals and Arrivo BioVentures.[1][3][6]

See also

[edit]

References

[edit]
  1. 1 2 3 4 5 6 "SP 624". AdisInsight. 29 August 2024. Retrieved 23 October 2024.
  2. 1 2 3 4 Raskin J, Clayton AH, Kornstein SG, Papakostas GI, Prescott Y, Abernathy K, et al. (September 2025). "A phase 2, multicenter, double-blind, randomized, placebo-controlled study of the safety and efficacy of forvisirvat (SP-624) in the treatment of adults with major depressive disorder". Curr Med Res Opin. 41 (9): 1723–1734. doi:10.1080/03007995.2025.2574465. PMID 41099447.
  3. 1 2 3 "Delving into the Latest Updates on SP-624 with Synapse". Synapse. 21 September 2024. Retrieved 23 October 2024.
  4. ↑ Rigdon G, Prescott Y, Hall J, Abernathy K, Raskin J, Wargin W (2025). "Phase 1, Single-Center, Double-Blind, Randomized, Placebo-Controlled Studies of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of the Sirtuin 6 Activator SP-624 in Healthy Adults". Clinical Pharmacology in Drug Development. 14 (1): 18–25. doi:10.1002/cpdd.1488. ISSN 2160-763X. PMC 11701958. PMID 39587867.
  5. 1 2 Liu R, Li Y, Zheng Q, Ding M, Zhou H, Li X (March 2024). "Epigenetic modification in liver fibrosis: Promising therapeutic direction with significant challenges ahead". Acta Pharmaceutica Sinica. B. 14 (3): 1009–1029. doi:10.1016/j.apsb.2023.10.023. PMC 10935124. PMID 38486982.
  6. 1 2 "Depression treatment shows 'robust efficacy' in women in phase 2 trial". Daily Medical News, Free CME and Clinical Guidance. 19 October 2022. Retrieved 23 October 2024.
  7. ↑ Zorko T, Kogovšek J, Ciber L, Ostojić I, Maraš N, Novinec M, et al. (March 2026). "Lead Optimization: Synthesis and Biological Evaluation of Griseofulvin Derivatives as Novel SIRT6 Activators". ACS Med Chem Lett. 17 (3): 662–669. doi:10.1021/acsmedchemlett.5c00690. PMC 12989997. PMID 41847663.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Forvisirvat&oldid=1357550453"